Establishment of an In Vitro Scab Model for Investigating Different Phases of Wound Healing

Chronic wounds are a serious problem in clinical work and a heavy burden for individuals and society. In order to develop novel therapies, adequate model systems for the investigation of wound healing are required. Although in past years different in vitro and in vitro wound healing models have been established, a true human-like model does still not exist. Animal models are limited in their use due to species-specific differences in the skin, a lengthy manufacturing process, experimental costs, and ethical concerns. Both 2D and 3D in vitro models are usually comprised of only one or two skin cell types and fail to capture the reaction between blood cells and skin cells. Thus, our aim was to develop an in vitro scab model to investigate early reactions in the wound healing process. The here established scab model is comprised of HaCaT cells and freshly collected blood from healthy volunteers. The generated scabs were stably cultured for more than 2 weeks. TGF-β signaling is well known to regulate the early phases of wound healing. All three TGF-β isoforms and target genes involved in extracellular matrix composition and degradation were expressed in the in vitro scabs. To validate the in vitro scab model, the effects of either additional stimulation or the inhibition of the TGF-β signaling pathway were investigated. Exogenous application of TGF-β1 stimulated matrix remodeling, which loosened the structure of the in vitro scabs with time, also induced expression of the inhibitory Smad7. Inhibition of the endogenous TGF-β signaling, on the contrary, resulted in a rapid condensation and degranulation of the in vitro scabs. In summary, the here established in vitro scab model can be used to analyze the first phases of wound healing where blood and skin cells interact, as it is viable and responsive for more than 2 weeks.

[1]  Wei-Qiang Tan,et al.  Current potential therapeutic strategies targeting the TGF-β/Smad signaling pathway to attenuate keloid and hypertrophic scar formation. , 2020, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  Guobing Chen,et al.  Upregulation of matrix metalloproteinase 9 (MMP9)/tissue inhibitor of metalloproteinase 1 (TIMP1) and MMP2/TIMP2 ratios may be involved in lipopolysaccharide-induced acute lung injury , 2020, The Journal of international medical research.

[3]  F. J. Nicolás,et al.  Role of TGF-β in Skin Chronic Wounds: A Keratinocyte Perspective , 2020, Cells.

[4]  P. Greenberg,et al.  MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways. , 2019, Blood advances.

[5]  A. Nussler,et al.  Impact of Four Protein Additives in Cryogels on Osteogenic Differentiation of Adipose-Derived Mesenchymal Stem Cells , 2019, Bioengineering.

[6]  P. Hoff,et al.  Hypoxia and mesenchymal stromal cells as key drivers of initial fracture healing in an equine in vitro fracture hematoma model , 2019, PloS one.

[7]  A. Nussler,et al.  Immune Cell Induced Migration of Osteoprogenitor Cells Is Mediated by TGF-β Dependent Upregulation of NOX4 and Activation of Focal Adhesion Kinase , 2018, International journal of molecular sciences.

[8]  T. Quan,et al.  Smad3-dependent CCN2 mediates fibronectin expression in human skin dermal fibroblasts , 2017, PloS one.

[9]  M. Ståhle,et al.  Transition from inflammation to proliferation: a critical step during wound healing , 2016, Cellular and Molecular Life Sciences.

[10]  V. Falanga,et al.  Transforming growth factor beta (TGF‐β) isoforms in wound healing and fibrosis , 2016, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[11]  R. Einspanier,et al.  Metalloproteinases and Their Tissue Inhibitors in Comparison between Different Chronic Pneumopathies in the Horse , 2015, Mediators of inflammation.

[12]  E. O’Toole,et al.  Metalloproteinases and Wound Healing. , 2015, Advances in wound care.

[13]  A. Ghahary,et al.  Critical Role of Transforming Growth Factor Beta in Different Phases of Wound Healing. , 2013, Advances in wound care.

[14]  H. Sorg,et al.  Wound Repair and Regeneration , 2012, European Surgical Research.

[15]  B. Alman,et al.  Fibronectin and β-Catenin Act in a Regulatory Loop in Dermal Fibroblasts to Modulate Cutaneous Healing* , 2011, The Journal of Biological Chemistry.

[16]  W. Parks,et al.  Metalloproteinases and their inhibitors: regulators of wound healing. , 2008, The international journal of biochemistry & cell biology.

[17]  M. Storck,et al.  [Chronic wounds--perspective for integrated care]. , 2007, Zentralblatt fur Chirurgie.

[18]  K. Lyons,et al.  CCN2 (Connective Tissue Growth Factor) is essential for extracellular matrix production and integrin signaling in chondrocytes , 2007, Journal of Cell Communication and Signaling.

[19]  Finn Gottrup,et al.  A specialized wound-healing center concept: importance of a multidisciplinary department structure and surgical treatment facilities in the treatment of chronic wounds. , 2004, American journal of surgery.

[20]  T. Yoshizaki,et al.  Cleavage of Syndecan-1 by Membrane Type Matrix Metalloproteinase-1 Stimulates Cell Migration* , 2003, Journal of Biological Chemistry.

[21]  I. Saiki,et al.  Effects of Recombinant Human Tissue Inhibitor of Metalloproteinases‐2 (rh‐TIMP‐2) on Migration of Epidermal Keratinocytes In vitro and Wound Healing In vivo , 2003, The Journal of dermatology.

[22]  U. Saarialho-Kere,et al.  Differential expression of tissue inhibitors of metalloproteinases (TIMP-1, -2, -3, and -4) in normal and aberrant wound healing. , 1999, Human pathology.

[23]  Gary R. Grotendorst,et al.  Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. , 1996, The Journal of investigative dermatology.

[24]  J. Kere,et al.  Patterns of matrix metalloproteinase and TIMP‐1 expression in chronic and normally healing human cutaneous wounds , 1996, The British journal of dermatology.

[25]  G. Schultz,et al.  Transforming growth factor beta 1 improves wound healing and random flap survival in normal and irradiated rats. , 1996, Archives of otolaryngology--head & neck surgery.

[26]  M. Sporn,et al.  Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[27]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[28]  A. Shortt,et al.  TGFbeta stimulated re-epithelialisation is regulated by CTGF and Ras/MEK/ERK signalling. , 2008, Experimental cell research.

[29]  A. Ludlow,et al.  Active transforming growth factor-beta in wound repair: determination using a new assay. , 1999, The American journal of pathology.

[30]  C. Heldin,et al.  Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. , 1997, Nature.

[31]  M. Sporn,et al.  TGF-beta: regulation of extracellular matrix. , 1992, Kidney international.

[32]  M. Sporn,et al.  Transforming growth factor-beta. Major role in regulation of extracellular matrix. , 1990, Annals of the New York Academy of Sciences.